CAESAREA, Israel, Aug. 13,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer minimally-invasive
cryoablation technology that destroys tumors by freezing as an
alternative to surgical tumor removal, announced today that it will
issue a press release with its financial and operational results as
of and for the six months ended June 30,
2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024. The Company will also
discuss such results and other corporate developments on a
conference call at 10:00 a.m. EDT on
the same day.
Conference call & webcast info:
Tuesday, August 20, 2024, at
10:00 am EDT
US: 1-888-407-2553
Israel/International:
+972-3-918-0696
A live webcast will be available
at:
https://Veidan.activetrail.biz/IcecureQ2-2024
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship ProSense® system
is marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe, and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses its
expected announcement of financial and operational results as of
and for the six months ended June 30,
2024, and hosting a conference call related to such results.
Because such statements deal with future events and are based on
IceCure's current expectations, they are subject to various risks
and uncertainties and actual results, performance, or achievements
of IceCure could differ materially from those described in or
implied by the statements in this press release. The
forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, many of which
are beyond the control of the Company, including those set forth
in the Risk Factors section of the Company's Annual Report on
Form 20-F for the year ended December 31,
2023 filed with the U.S. Securities and Exchange Commission
(the "SEC") on April 3, 2024, and
other documents filed with or furnished to the SEC which are
available on the SEC's website, www.sec.gov. The Company undertakes
no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-second-quarter-2024-financial--operational-results-on-august-20-2024-302221006.html
SOURCE IceCure Medical